Meeting
2018 ASCO Annual Meeting
Systematic review of pediatric oncology phase I trials: Toxicity and outcomes in the era of targeted therapies.
Authors
Julia Wanda Cohen
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
Julia Wanda Cohen , Srivandana Akshintala , Eli Kane , Seth M. Steinberg , Brigitte C. Widemann , Nirali N. Shah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Conduct of Clinical Research
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2536)
DOI
10.1200/JCO.2018.36.15_suppl.2536
Abstract #
2536
Poster Bd #
362
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience.
First Author: Han Hsi Wong
Poster
2013 ASCO Annual Meeting
Novel toxicity endpoint for dose-finding designs evaluating molecularly targeted agents (MTA).
First Author: Monia Ezzalfani
Poster
2023 ASCO Annual Meeting
Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials.
First Author: Avina Rami
Poster
2023 ASCO Annual Meeting
Utilizing Drug Combo to improve the design of phase 1 trials for anticancer drugs.
First Author: Lei Wang